Mankind Pharma receives a 'Buy' recommendation from Investec due to its strategic BSV partnership, expected to improve IVF market sales and drive growth.
Mankind Pharma, India’s fourth-largest pharmaceutical firm, is recommended as a 'Buy' by Investec due to its strategic partnership with Bharat Serums and Vaccines (BSV). This collaboration is expected to enhance sales and drive growth, particularly in the IVF market. Mankind plans to raise ₹10,000 crore through non-convertible debentures and commercial papers, following its acquisition of BSV for ₹13,630 crore. Recent strong performance has further boosted investor confidence.
September 20, 2024
7 Articles